Shortage Notice: Provera (medroxyprogesterone acetate) 100mg & 200mg tablets Updated 15th November 2019

Shortage Notice: Provera (medroxyprogesterone acetate) 100mg & 200mg tablets Updated 15th November 2019

November 15, 2019

MSN/2019/008U

Date issued: 14/11//2019

Pfizer, the sole supplier of Provera tablets, are experiencing manufacturing delays, and are out of stock of the 100mg and 200mg  tablets.

Resupply of Provera 100mg tablets is delayed until 13th December 2019

Provera 200mg tablets are now out of stock until 20th December 2019

Provera 400mg tablets are available, but cannot support an increase in demand.

Unlicensed imports of medroxyprogesterone 100mg tablets remain available.

For guidance on alternative agents and management options please see the shortage of supply memo here.

Pharmacy team are reminded that where a prescriber wishes you to dispense an import, prescriptions must be annotated ‘Special Order’. All prescriptions for unlicensed medicines should be placed in the red separators for the end of month submission.

A prescription calling for the unlicensed product should be endorsed as follows:

  • Quantity dispensed
  • Pack size
  • Price per unit less any discount/rebate
  • Manufacturer/importer MHRA license number
  • Batch number
  • Specials procurement fee endorsement of ‘SP’

See our factsheet for further guidance on endorsing unlicensed specials and imports.

For more information on medicines shortages, click here.

To report a medicine shortage, click here.



Posted in: ,


More Latest News >

PQS: NSAID quality criterion

This news story highlights several points on the non-steroidal anti-inflammatory drug (NSAID) quality criterion of the Pharmacy Quality Scheme (PQS)...